Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. (Q50979570)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ilijas Jelčić

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Roland Martin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mireia Sospedra

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

Sven Schippling

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

27 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

790-798

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Interaction of the human polyomavirus, JCV, with human B-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

"Thinking without thinking" about natalizumab and PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Integrin-mediated long-term B cell retention in the splenic marginal zone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Integrin-dependence of lymphocyte entry into the splenic white pulp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

The bone marrow, B cells, and JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Regulation of follicular B cell differentiation by the related E26 transformation-specific transcription factors PU.1, Spi-B, and Spi-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142108

7 January 2021

Identifiers

DOI

10.1002/EJI.201142108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22144343%20AND%20SRC:MED&resulttype=core&format=json

release_rytnzak77vghvoes5e4unf6tpm

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rytnzak77vghvoes5e4unf6tpm

24 November 2022

mapped directly with Wikidata item

1 reference